Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14606816 | 0.84 | PTGS2 (0.36) | IDO1ALDH1A1PTGS2CYP1A2CYP2A6 | |
| SCHEMBL9734683 | 0.84 | PTGS2 (0.36) | IDO1ALDH1A1PTGS2CYP1A2CYP2A6 | |
| SCHEMBL27299823 | 0.81 | ALDH1A1 (0.35) | IDO1ALDH1A1GAAALOX12HTT | |
| SCHEMBL25628415 | 0.79 | ADRB1 (0.33) | ADRB1ADRB2PTGS2 | |
| SCHEMBL15249714 | 0.78 | PLG (0.33) | IDO1PTGS2CYP1A2CYP2A6 | |
| SCHEMBL7042571 | 0.78 | NOS3 (0.41) | ALDH1A1NOS3NOS1NOS2PTGS2 | |
| SCHEMBL2377994 | 0.78 | ALDH1A1 (0.41) | IDO1ALDH1A1GAAALOX12HTT | |
| SCHEMBL10890708 | 0.78 | ALDH1A1 (0.41) | ALDH1A1GAAALOX12HTTHIF1A | |
| SCHEMBL397098 | 0.78 | NOS3 (0.41) | ALDH1A1GAANOS3NOS1NOS2 | |
| SCHEMBL10526433 | 0.77 | PTGS2 (0.32) | IDO1PTGS2CYP1A2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459925-B2 | Sulphonyl urea derivatives as NLRP3 inflammasome modulators | NodThera Limited (GB) | 2025-11-04 | — | — | US | disclosed |
| EP-3728238-B1 | SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS | NODTHERA LTD (GB) | 2025-06-18 | — | — | EP | disclosed |
| US-20240368129-A1 | SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS | NodThera Limited (GB) | 2024-11-07 | — | — | US | disclosed |
| US-12012397-B2 | Sulphonyl urea derivatives as NLRP3 inflammasome modulators | NodThera Limited (GB) | 2024-06-18 | — | — | US | disclosed |
| EP-4210454-A1 | LIGHT-EMITTING DEVICE AND ELECTRONIC APPARATUS INCLUDING THE SAME | Samsung Display Co., Ltd. (KR) | 2023-07-12 | — | — | EP | disclosed |
| US-20230145050-A1 | SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS | NodThera Limited (GB) | 2023-05-11 | — | — | US | disclosed |
| US-11518757-B2 | Sulphonyl urea derivatives as NLRP3 inflammasome modulators | NodThera Limited (GB) | 2022-12-06 | — | — | US | disclosed |
| US-20210002261-A1 | SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS | NodThera Limited (GB) | 2021-01-07 | — | — | US | disclosed |
| CN-111954670-A | Sulfonylurea derivatives as NLRP3 inflammasome modulators | 诺瑟拉有限公司 | 2020-11-17 | — | — | CN | disclosed |
| EP-3728238-A1 | SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS | Nodthera Limited (GB) | 2020-10-28 | — | — | EP | disclosed |
| US-20180079781-A1 | BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-22 | — | — | US | disclosed |
| US-9822144-B2 | Benzodiazepine dimers, conjugates thereof, and methods of making and using | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12012397-B2 | Sulphonyl urea derivatives as NLRP3 inflammasome modulators | NLRP3, NOD1, IL1B | IDO1 928/4885ALDH1A1 612/4885GAA 3359/4885 |
| US-20230145050-A1 | SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS | NLRP3, NOD1, IL1B | IDO1 928/4885ALDH1A1 612/4885GAA 3359/4885 |
| US-20240368129-A1 | SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS | NLRP3, NOD1, IL1B | IDO1 928/4885ALDH1A1 612/4885GAA 3359/4885 |
| US-11518757-B2 | Sulphonyl urea derivatives as NLRP3 inflammasome modulators | NLRP3, NOD1, IL1B | IDO1 928/4885ALDH1A1 612/4885GAA 3359/4885 |
| US-20210002261-A1 | SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS | NLRP3, NOD1, IL1B | IDO1 928/4885ALDH1A1 612/4885GAA 3359/4885 |
| US-20180079781-A1 | BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | GABRA1, GABRA3, GABRA2 | IDO1 2338/4885ALDH1A1 164/4885GAA 4092/4885 |
| US-12459925-B2 | Sulphonyl urea derivatives as NLRP3 inflammasome modulators | NLRP3, NOD1, IL1B | IDO1 928/4885ALDH1A1 612/4885GAA 3359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.